Cargando…
Development of a rapid phenotypic test for HCV protease inhibitors with potential use in clinical decisions
Approximately 185 million people worldwide are chronically infected with hepatitis C virus (HCV). The first-wave of approved NS3 protease inhibitors (PIs) were Telaprevir and Boceprevir, which are currently discontinued. Simeprevir is a second-wave PI incorporated into the Brazilian hepatitis C trea...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Sociedade Brasileira de Genética
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5004841/ https://www.ncbi.nlm.nih.gov/pubmed/27575432 http://dx.doi.org/10.1590/1678-4685-GMB-2016-0022 |